Drug Monograph

Drug/Drug Class:	**Actemra® ACTPen™ (tocilizumab) solution for injection / Targeted Immunomodulators**
Prepared for:	MO HealthNet
Prepared by:	Conduent

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Actemra® ACTPen™ is available in a single-dose prefilled syringe or autoinjector containing 162 mg of tocilizumab per 0.9 ml solution.
Manufacturer:	Genentech, Inc., South San Francisco, CA 94080
Indications:	Actemra® ACTPen™ is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis, giant cell arteritis, active polyarticular and systemic juvenile idiopathic arthritis in patients 2 years of age and older, and chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome in adults and pediatric patients 2 years of age and older.
Costs:	$968.96 per pen of Actemra® ACTPen™. Maximum Allowable Cost
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List (PDL) as non-preferred
Status Recommendation:	☐ Prior Authorization (PA) Required ☐ Open Access ☐ Fiscal Edit ☒ PDL
Type of PA Criteria:	☐ Increased Risk of ADE ☒ Non-Preferred ☐ Appropriate Indications ☐ No PA Required

Prepared by: Luke Boehmer PharmD
Date: February 26, 2019